Randomized Trialhigh evidence
Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·October 26, 2026·PMID 42933637
Why it mattersPatients with relapsed/refractory osteosarcoma have limited effective options after multiple lines of therapy. This trial provides evidence that a targeted antibody-drug conjugate can meaningfully delay progression compared with standard chemotherapy, offering a potential new treatment avenue for this difficult-to-treat population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled